Online inquiry

IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12080MR)

This product GTTS-WQ12080MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12080MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1451MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ8806MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ3890MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-100
GTTS-WQ6690MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ2427MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ5939MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ10397MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ8398MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HS006
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW